Abstract
Capuramycin (CM) antibiotics are bactericidal for Mycobacterium tuberculosis (MTB) in vitro. Due to their low membrane permeability and efflux, however, these compounds are less effective against intracellular MTB. To improve intracellular activity, we created phospholipid Phosal 53 MCT-based nanoemulsion (NE) formulations of CM analogues SQ641, SQ641-aua, SQ641-2aua and SQ997-3aua. We assessed intracellular killing activity of the 4 CM analogues and their NE formulations against MTB using the J774A.1 mouse macrophage cell line. Of the several emulsifiers investigated, d-tocopheryl polyethylene glycol 1000 succinate (TPGS) produced the most efficacious and stable emulsion, with a mean particle size below 70 nm. CM analogue-NE formulations prepared using TPGS as emulsifier (-NETPGS) showed significantly improved intracellular activity over free drugs. The order of intracellular activity was SQ641-2aua- NETPGS > SQ997-3aua-NETPGS > SQ641-aua-NETPGS > SQ641-NETPGS. At 2× MIC the intracellular killing activity of SQ641- 2aua-NETPGS, the most active formulation, surpassed that of first-line anti-TB drugs isoniazid (INH), rifampin (RIF) and ethambutol (EMB). Enhanced intracellular activity of the -NETPGS formulation, perhaps, was due to TPGS mediated blocking of the drug efflux.
Keywords: Anti-TB drugs, SQ641, phospholipids, nanoemulsion, M.tuberculosis, intracellular activity, capuramycin, Intracellular Drug Activity, CM Analogues, emulsifiers
Drug Delivery Letters
Title: Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis
Volume: 1 Issue: 2
Author(s): Venkata M. Reddy, Elena Bogatcheva, Leo Einck and Carol A. Nacy
Affiliation:
Keywords: Anti-TB drugs, SQ641, phospholipids, nanoemulsion, M.tuberculosis, intracellular activity, capuramycin, Intracellular Drug Activity, CM Analogues, emulsifiers
Abstract: Capuramycin (CM) antibiotics are bactericidal for Mycobacterium tuberculosis (MTB) in vitro. Due to their low membrane permeability and efflux, however, these compounds are less effective against intracellular MTB. To improve intracellular activity, we created phospholipid Phosal 53 MCT-based nanoemulsion (NE) formulations of CM analogues SQ641, SQ641-aua, SQ641-2aua and SQ997-3aua. We assessed intracellular killing activity of the 4 CM analogues and their NE formulations against MTB using the J774A.1 mouse macrophage cell line. Of the several emulsifiers investigated, d-tocopheryl polyethylene glycol 1000 succinate (TPGS) produced the most efficacious and stable emulsion, with a mean particle size below 70 nm. CM analogue-NE formulations prepared using TPGS as emulsifier (-NETPGS) showed significantly improved intracellular activity over free drugs. The order of intracellular activity was SQ641-2aua- NETPGS > SQ997-3aua-NETPGS > SQ641-aua-NETPGS > SQ641-NETPGS. At 2× MIC the intracellular killing activity of SQ641- 2aua-NETPGS, the most active formulation, surpassed that of first-line anti-TB drugs isoniazid (INH), rifampin (RIF) and ethambutol (EMB). Enhanced intracellular activity of the -NETPGS formulation, perhaps, was due to TPGS mediated blocking of the drug efflux.
Export Options
About this article
Cite this article as:
M. Reddy Venkata, Bogatcheva Elena, Einck Leo and A. Nacy Carol, Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis, Drug Delivery Letters 2011; 1 (2) . https://dx.doi.org/10.2174/2210304x11101020150
DOI https://dx.doi.org/10.2174/2210304x11101020150 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Synthesis and In Vitro Evaluation of Some Hydrazone Derivatives as Potential Antibacterial Agents
Letters in Drug Design & Discovery The Mode of Inhibition of Mycobacterium tuberculosis Wild-Type and Isoniazid-Resistant 2-Trans-Enoyl-ACP(CoA) Reductase Enzymes by An Inorganic Complex
Anti-Infective Agents in Medicinal Chemistry Chemical Composition and Antibacterial Potential of Essential Oils from Artemisia Capillaris, Artemisia Nilagirica, Citrus Limon, Cymbopogon Flexuosus, Hedychium Spicatum and Ocimum Tenuiflorum
The Natural Products Journal Inside the Pan-genome - Methods and Software Overview
Current Genomics Bacterial Resistance to Antimicrobial Host Defenses - An Emerging Target for Novel Antiinfective Strategies?
Current Drug Targets An Overwiev of ORF Virus Infection in Humans and Animals
Recent Patents on Anti-Infective Drug Discovery Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews 13-lncRNAs Signature to Improve Diagnostic and Prognostic Prediction of Hepatocellular Carcinoma
Combinatorial Chemistry & High Throughput Screening NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design
Current Medicinal Chemistry Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry A Bibliometric Analysis of Global Research on Lophomonas Spp. in Scopus (1933-2019)
Infectious Disorders - Drug Targets Pharmacological Targeting of the Inflamed Intestinal Barrier
Current Pharmaceutical Design Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets New Aminoacyl-tRNA Synthetase Inhibitors as Antibacterial Agents
Current Drug Targets - Infectious Disorders Type 2 Diabetes and its Impact on the Immune System
Current Diabetes Reviews